9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Estimated reading time: < 1 min

Condition: Advanced Malignancies

Estimated Enrollment: 10

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],  Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,  Phase 2: Complete response rate (CRR) based on RECIST v1.1, Phase 1: ORR based on RECIST v1.1 and mRECIST

Interventions: INCAGN01876, Epacadostat

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 2020

Completion Date: May 2020

Last  Posted Date: May 7, 2019

Location: The Angeles Clinic and Research Institute, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03277352

Was this article helpful?
Dislike 0